{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:23:19Z","timestamp":1777072999518,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jgar.2017.04.012","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T02:31:47Z","timestamp":1500345107000},"page":"291-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim\/sulfamethoxazole and doxycycline by the microbroth dilution method"],"prefix":"10.1016","volume":"10","author":[{"given":"Samuel","family":"Maloney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.04.012_bib0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1204699","article-title":"Melioidosis","volume":"367","author":"Wiersinga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2017.04.012_bib0010","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(03)13374-0","article-title":"Melioidosis","volume":"361","author":"White","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2017.04.012_bib0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0035-9203(00)90333-X","article-title":"Melioidosis: acute and chronic disease, relapse and re-activation","volume":"94","author":"Currie","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jgar.2017.04.012_bib0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QCO.0b013e32833fb88c","article-title":"Melioidosis: advances in diagnosis and treatment","volume":"23","author":"Cheng","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jgar.2017.04.012_bib0025","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http:\/\/www.eucast.org. [Accessed 4 August 2017]."},{"key":"10.1016\/j.jgar.2017.04.012_bib0030","series-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline\u2014second edition","author":"Clinical and Laboratory Standards Institute","year":"2010"},{"key":"10.1016\/j.jgar.2017.04.012_bib0035","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2017.04.012_bib0040","unstructured":"European Committee on Antimicrobial Susceptibility Testing. External documents. http:\/\/www.eucast.org\/documents\/external_documents\/. [Accessed 14 December 2016]."},{"key":"10.1016\/j.jgar.2017.04.012_bib0045","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. http:\/\/mic.eucast.org\/Eucast2\/. [Accessed 20 October 2016]."},{"key":"10.1016\/j.jgar.2017.04.012_bib0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.04.012_bib0055","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jgar.2017.04.012_bib0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.03.00006203","article-title":"Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions","volume":"22","author":"Currie","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2017.04.012_bib0065","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(89)90768-X","article-title":"Halving of mortality of severe melioidosis by ceftazidime","volume":"2","author":"White","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2017.04.012_bib0070","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1128\/AAC.47.7.2082-2087.2003","article-title":"Burkholderia pseudomallei class A \u03b2-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition","volume":"47","author":"Tribuddharat","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.012_bib0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijantimicag.2014.04.012","article-title":"Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia","volume":"44","author":"Crowe","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.04.012_bib0080","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2015.01.006","article-title":"Trimethoprim\/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand","volume":"45","author":"Saiprom","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.04.012_bib0085","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijantimicag.2014.06.003","article-title":"Trimethoprim\/sulfamethoxazole resistance in Burkholderia pseudomallei","volume":"44","author":"Dance","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.04.012_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0924-8579(00)00334-4","article-title":"Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis","volume":"17","author":"Jenney","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.04.012_bib0095","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/AAC.01301-08","article-title":"Dosing regimens of cotrimoxazole (trimethoprim\u2013sulfamethoxazole) for melioidosis","volume":"53","author":"Cheng","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2017.04.012_bib0100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(13)61951-0","article-title":"Trimethoprim\u2013sulfamethoxazole versus trimethoprim\u2013sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial","volume":"383","author":"Chetchotisakd","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2017.04.012_bib0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2006.01617.x","article-title":"The contribution of pharmacokinetic\u2013pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis","volume":"13","author":"Burgess","year":"2007","journal-title":"Clin Microbiol Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517300930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T05:01:42Z","timestamp":1535605302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517300930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":21,"alternative-id":["S2213716517300930"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.04.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim\/sulfamethoxazole and doxycycline by the microbroth dilution method","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.","name":"copyright","label":"Copyright"}]}}